Related Experiment Videos
Susceptibility of bacterial isolates from AIDS patients to six fluoroquinolones
Abstract:
The susceptibilities to ciprofloxacin, DR-3355 (S-(-)-ofloxacin), enoxacin, lomefloxacin, ofloxacin and PD127,391 of 69 significant bacterial isolates from HIV-positive patients at the City Hospital, Edinburgh have been determined. With the exception of the enterococci, most of the strains tested (including staphylococci, Escherichia coli and Pseudomonas aeruginosa) were susceptible to the fluoroquinolones. Ciprofloxacin was the most active of the clinically available drugs followed by ofloxacin, lomefloxacin and enoxacin. PD127,391 and DR-3355, the new fluoroquinolones tested, were at least as active as ciprofloxacin. Hence bacterial infections in AIDS patients should respond to fluoroquinolone therapy.
Insights
This study assessed fluoroquinolone effectiveness against bacterial isolates from HIV-positive patients. Most bacteria, excluding enterococci, showed susceptibility, indicating potential efficacy of fluoroquinolone therapy for AIDS patients.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Bacterial infections pose significant risks to individuals with Human Immunodeficiency Virus (HIV).
- Fluoroquinolones are a class of antibiotics with broad-spectrum activity.
- Understanding antibiotic susceptibility patterns is crucial for effective treatment of opportunistic infections in immunocompromised patients.
Purpose of the Study:
- To determine the in vitro susceptibilities of significant bacterial isolates from HIV-positive patients to various fluoroquinolone antibiotics.
- To compare the activity of established fluoroquinolones with newer agents against these clinical isolates.
Main Methods:
- Sixty-nine bacterial isolates from HIV-positive patients were collected from the City Hospital, Edinburgh.
- Susceptibility testing was performed for ciprofloxacin, DR-3355 (S-(-)-ofloxacin), enoxacin, lomefloxacin, ofloxacin, and PD127,391.
- Bacterial strains included staphylococci, Escherichia coli, Pseudomonas aeruginosa, and enterococci.
Main Results:
- Most tested bacterial strains, including Staphylococcus species, Escherichia coli, and Pseudomonas aeruginosa, demonstrated susceptibility to the fluoroquinolones.
- Enterococci were an exception, showing lower susceptibility.
- Ciprofloxacin exhibited the highest activity among the clinically available drugs, followed by ofloxacin, lomefloxacin, and enoxacin.
- The novel fluoroquinolones, PD127,391 and DR-3355, displayed activity comparable to or greater than ciprofloxacin.
Conclusions:
- The study suggests that fluoroquinolone antibiotics are effective against a wide range of bacterial pathogens commonly found in HIV-positive patients.
- These findings support the potential utility of fluoroquinolone therapy for treating bacterial infections in patients with Acquired Immunodeficiency Syndrome (AIDS).
- Further clinical evaluation may be warranted to confirm the efficacy of these agents in this patient population.